Real-world effectiveness of vedolizumab in refractory pouchitis: a focus on biomarker changes during intravenous to subcutaneous transition (POUCHIVED study).

Front Immunol · 2025 · PMC12753362 · PMID 41479913

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Similarly, FC levels showed a decreasing trend over time from a baseline median of 443 μg/g (IQR 213-746) to 329 μg/g (145-701) at week 12, 193 μg/g (91-412) at week 24 and 178 μg/g (101-640) at week 52.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.